INmune Bio Announces $13M Registered Direct Offering
Portfolio Pulse from Benzinga Newsdesk
INmune Bio Inc. (NASDAQ:INMB) announced a $13M registered direct offering involving the sale of common stock and warrants to institutional investors and insiders. The proceeds will be used for working capital and general corporate purposes.
September 13, 2024 | 12:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
INmune Bio's $13M registered direct offering involves selling shares and warrants to institutional investors and insiders. This move is expected to provide the company with additional working capital.
The direct offering will provide INmune Bio with $13M in gross proceeds, enhancing its financial position. The involvement of institutional investors and insiders suggests confidence in the company's prospects, potentially leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100